No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy

[1]  F. Carrilho,et al.  Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: Novel insights about targeted genotyping approaches , 2014, Journal of medical virology.

[2]  J. Howe,et al.  Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin , 2014, Open forum infectious diseases.

[3]  H. Fleury,et al.  Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia , 2014, Journal of medical virology.

[4]  Yoshiyuki Suzuki,et al.  Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b , 2014, Journal of medical virology.

[5]  P. Trembling,et al.  Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. , 2014, Antiviral research.

[6]  A. Craxì,et al.  HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[7]  Ester C. Sabino,et al.  HCV Genotypes, Characterization of Mutations Conferring Drug Resistance to Protease Inhibitors, and Risk Factors among Blood Donors in São Paulo, Brazil , 2014, PloS one.

[8]  O. Yokosuka,et al.  Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. , 2013, World journal of gastroenterology.

[9]  G. Kukolj,et al.  Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir , 2013, Antimicrobial Agents and Chemotherapy.

[10]  D. Hazuda,et al.  Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. , 2013, Virology.

[11]  G. Kukolj,et al.  Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study , 2013, Antimicrobial Agents and Chemotherapy.

[12]  Yoshiyuki Suzuki,et al.  Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1 , 2013, Journal of Clinical Microbiology.

[13]  G. Silva,et al.  Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors , 2013, Memorias do Instituto Oswaldo Cruz.

[14]  G. Raimondo,et al.  Ns3 Genetic Variability in HCV Genotype-1B Isolates from Liver Specimens and Blood Samples of Treatment-Naive Patients with Chronic Hepatitis C , 2013, Antiviral therapy.

[15]  G. Stańczak,et al.  Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients. , 2013, Przeglad epidemiologiczny.

[16]  E. Rondinelli,et al.  Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study , 2013, Virology Journal.

[17]  F. Baldanti,et al.  Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients , 2012, Virology Journal.

[18]  Tara L. Kieffer,et al.  Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir , 2012, PloS one.

[19]  M. Zazzi,et al.  Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. , 2012, The Journal of antimicrobial chemotherapy.

[20]  X. Tong,et al.  Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b , 2012, Journal of viral hepatitis.

[21]  N. Enomoto,et al.  Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients , 2012, Hepatology International.

[22]  A. Aghemo,et al.  Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C , 2010, Nature Reviews Gastroenterology &Hepatology.

[23]  E. Lampe,et al.  Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients , 2010, Archives of Virology.

[24]  F. Hamzeh,et al.  Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. , 2009, The New England journal of medicine.

[25]  Tara L. Kieffer,et al.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. , 2008, The Journal of infectious diseases.

[26]  H. Niesters,et al.  Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.